Page last updated: 2024-11-06

ribostamycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ribostamycin is an aminoglycoside antibiotic produced by the bacterium *Streptomyces ribosidificus*. It has a broad spectrum of activity against Gram-negative bacteria, including *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. Ribostamycin inhibits protein synthesis by binding to the 16S rRNA of the 30S subunit of bacterial ribosomes, leading to misreading of mRNA and the production of non-functional proteins. This antibiotic is effective against a variety of infections, including respiratory, urinary, and skin infections. It is also effective against multi-drug resistant strains of bacteria, making it a valuable treatment option. Ribostamycin is a potent antibiotic with a unique mechanism of action. It is often used in combination with other antibiotics to increase its effectiveness and reduce the risk of resistance. Researchers are studying ribostamycin's potential in combination therapies for infections caused by multi-drug resistant bacteria.'

Ribostamycin: A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ribostamycin : An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID33042
CHEMBL ID221572
CHEBI ID45257
SCHEMBL ID1649929
MeSH IDM0019082

Synonyms (56)

Synonym
chebi:45257 ,
CHEMBL221572
o-2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranosyl-(1->4)-o-[.beta.-d-ribofuranosyl-(1->5)]-2-deoxy-d-streptamine
xylostatin
(2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]oxy-3-hydroxy-cyclohexoxy]tetrahydropyran-3,4-diol
hetangmycin
NSC138925 ,
RIO ,
ribostamycin
C01759
vistamycin
25546-65-0
DB03615
ribostamycin a
bu 1709
ribastamin
sf 733
antibiotic sf 733
nsc-138925
ribostamycinum [inn-latin]
dekamycin iv
ribostamicina [inn-spanish]
sf-733
d-streptamine, o-2,6-diamino-2,6-dideoxy-alpha-d-glucopyranosyl-(1-4)-o-(beta-d-ribofuranosyl-(1-5))-2-deoxy-
brn 1357280
d-streptamine, o-2,6-diamino-2,6-dideoxy-alpha-d-glucopyranosyl-(1-4)- o-(beta-d-ribofuranosyl-(1-5))-2-deoxy-
nsc 138925
o-2,6-diamino-2,6-dideoxy-alpha-d-glucopyranosyl-(1-4)-o-(beta-d-ribofuranosyl-(1-5))-2-deoxystreptamine
ribostamycine [inn-french]
ribostamycin [inn:ban]
einecs 247-091-5
o-2,6-diamino-2,6-dideoxy-alpha-d-glucopyranosyl-(1->4)-o-(beta-d-ribofuranosyl-(1->5))-2-deoxystreptamine
(2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
D08478
ribostamycin (inn)
(1r,2r,3r,4r,6s)-4,6-diamino-3-hydroxy-2-(beta-d-ribofuranosyloxy)cyclohexyl 2,6-diamino-2,6-dideoxy-alpha-d-glucopyranoside
ribostamycine
ribostamycinum
ribostamicina
2q5jou7t53 ,
unii-2q5jou7t53
ribostamycin [inn]
d-streptamine, o-2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(.beta.-d-ribofuranosyl-(1->5))-2-deoxy-
ribostamycin [who-dd]
ribostamycin [mi]
o-2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(.beta.-d-ribofuranosyl-(1->5))-2-deoxystreptamine
NSKGQURZWSPSBC-VVPCINPTSA-N
SCHEMBL1649929
DTXSID6048541
(1r,2r,3s,4r,6s)-4,6-diamino-3-hydroxy-2-(beta-d-ribofuranosyloxy)cyclohexyl 2,6-diamino-2,6-dideoxy-alpha-d-glucopyranoside
HY-142127
CS-0378913
EN300-19766281
(2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-{[(1r,2r,3s,4r,6s)-4,6-diamino-2-{[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol
gtpl12161
(2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-(((1r,2r,3s,4r,6s)-4,6-diamino-2-(((2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3-hydroxycyclohexyl)oxy)tetrahydro-2h-pyran-3,4-diol

Research Excerpts

Overview

Ribostamycin is a broad-spectrum aminoglycoside antibiotic with a molecular weight of 454.5 g/mol. It is naturally produced by Streptomyces ribosidificus.

ExcerptReferenceRelevance
"Ribostamycin is a broad-spectrum aminoglycoside antibiotic with a molecular weight of 454.5 g/mol. "( Linear self-assembly formation between gold nanoparticles and aminoglycoside antibiotics.
Huo, Q; Leong, MB; Li Sip, YY; Zheng, T, 2018
)
1.92
"Ribostamycin is a 4,5-disubstituted 2-deoxystreptamine (DOS)-containing aminoglycoside antibiotics and naturally produced by Streptomyces ribosidificus ATCC 21294. "( Biosynthesis of ribostamycin derivatives by reconstitution and heterologous expression of required gene sets.
Kurumbang, NP; Liou, K; Sohng, JK, 2011
)
2.16
"Ribostamycin is an aminoglycoside antibiotic produced by Streptomyces ribosidificus, and extracted and isolated by NIIDA et. "( Pharmacokinetics of ribostamycin in healthy volunteers and patients with impaired renal function.
Suzuki, Y; Umemura, K; Yamasaku, F, 1980
)
2.03

Pharmacokinetics

ExcerptReferenceRelevance
" All pharmacokinetic parameters and statistical analyses were calculated by computer."( Pharmacokinetics of ribostamycin in paediatric patients.
Shen, G; Zhong, HF; Zhou, SL, 1992
)
0.61
" studied the pharmacokinetics of this antibiotic in animals and reported that it has a similar pharmacokinetic behavior in vivo to kanamycin."( Pharmacokinetics of ribostamycin in healthy volunteers and patients with impaired renal function.
Suzuki, Y; Umemura, K; Yamasaku, F, 1980
)
0.58
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Dosage Studied

Ribostamycin caused slightly less nephrotoxicity in rats than kanamycin and far less than dibekacin at an equal dosage of 40 mg/kg per day for 14 days.

ExcerptRelevanceReference
" Ribostamycin caused slightly less nephrotoxicity in rats than kanamycin and far less than dibekacin at an equal dosage of 40 mg/kg per day for 14 days."( Comparative nephrotoxicity of ribostamycin and gentamicin in rats evaluated by urinalysis.
Inouye, S; Kitasato, I; Niizato, T, 1989
)
1.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
amino cyclitol glycoside
aminoglycoside antibiotic
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aminoglycoside 3'-phosphotransferase Pseudomonas aeruginosa PAO1Km10.000010.000010.000010.0000AID278807
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (53)

Assay IDTitleYearJournalArticle
AID428870Antibacterial activity against Escherichia coli CSH-2 carrying Escherichia coli ARS3 pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID301914Antibacterial activity against aminoglycoside-resistant Escherichia coli TG1 pSF815 after 12 to 18 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis and antibacterial activity of pyranmycin derivatives with N-1 and O-6 modifications.
AID1629128Antimicrobial activity against Escherichia coli ATCC 25922 measured after 24 hrs by double-dilution method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID523405Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID199517Compound was tested for the inhibition of Rev-RBE RNA complex formation1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex.
AID1629132Antimicrobial activity against aminoglycoside-resistant Klebsiella pneumoniae ATCC BAA-2470 measured after 24 hrs by double-dilution method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID1629126Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 measured after 24 hrs by double-dilution method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID278811Ratio of km to kcat for PH(3')-2b activity2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID664696Antimicrobial activity against Staphylococcus aureus ATCC 292132011ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue.
AID1629127Antimicrobial activity against Klebsiella pneumoniae ATCC 10031 measured after 24 hrs by double-dilution method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID278810Antibacterial activity against Escherichia coli BL21(DE3) expressing Pseudomonas aeruginosa APH(3')-2b2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa.
AID428879Binding affinity to 16S rRNA G1494(N7) position in A1408-methylated Escherichia coli JM109 30S sunit at 1000 uM by footprint assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID523397Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID375076Binding affinity to A-site RNA2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Design and implementation of an ribonucleic acid (RNA) directed fragment library.
AID428878Binding affinity to 16S rRNA G1494(N7) position in A1408-methylated Escherichia coli JM109 30S sunit at 100 uM by footprint assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID301912Antibacterial activity against Escherichia coli ATCC 25922 after 12 to 18 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis and antibacterial activity of pyranmycin derivatives with N-1 and O-6 modifications.
AID428876Binding affinity to 16S rRNA G1494(N7) position in wild type Escherichia coli JM109 30S sunit at 100 uM by footprint assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID1629130Antimicrobial activity against aminoglycoside-resistant Burkholderia cepacia ATCC 25416 measured after 24 hrs by double-dilution method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID428872Antibacterial activity against Escherichia coli JM109 carrying pMCL-BE by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID523398Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 5 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID1629131Antimicrobial activity against aminoglycoside-resistant Escherichia coli ATCC BAA-2452 measured after 24 hrs by double-dilution method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID428871Antibacterial activity against Escherichia coli CSH-2 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID65062Lethal dose required to kill 90% of the Escherichia coli K12 (ATCC 25868) cell population1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID301915Antibacterial activity against aminoglycoside-resistant Escherichia coli TG1 pTZ19U-3 after 12 to 18 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis and antibacterial activity of pyranmycin derivatives with N-1 and O-6 modifications.
AID1629134Inhibition of cytosolic eukaryotic translation in rabbit reticulocyte S30 extract measured after 60 mins by coupled transcription/translation-based luciferase reporter gene assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID271282Binding affinity to bacterial ribosomal A site RNA oligonucleotide2006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Binding of aminoglycosidic antibiotics to the oligonucleotide A-site model and 30S ribosomal subunit: Poisson-Boltzmann model, thermal denaturation, and fluorescence studies.
AID664699Antimicrobial activity against Staphylococcus aureus harboring APH(2'''') and AAC(6') enzymes2011ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue.
AID428877Binding affinity to 16S rRNA G1494(N7) position in wild type Escherichia coli JM109 30S sunit at 1000 uM by footprint assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID1629125Antimicrobial activity against Haemophilus influenzae ATCC 10211 measured after 24 hrs by double-dilution method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID278809Antibacterial activity against Escherichia coli BL21(DE3)2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa.
AID1629123Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 measured after 24 hrs by double-dilution method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID428873Antibacterial activity against Escherichia coli JM109 carrying pMCL210 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID523396Antimicrobial activity against amikacin-resistant Nocardia farcinica IFM 10580 after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID1629135Selectivity ratio, ratio of IC50 for cytosolic eukaryotic translation in rabbit reticulocyte S30 extract to IC50 for 16S rRNA A-site in Escherichia coli S30 extract2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID278807Activity against Pseudomonas aeruginosa APH(3')-2b expressed in Escherichia coli BL21(DE3) assessed as phosphorylation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa.
AID301913Antibacterial activity against aminoglycoside-susceptible Escherichia coli TG1 after 12 to 18 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis and antibacterial activity of pyranmycin derivatives with N-1 and O-6 modifications.
AID65071Estimated rate of [3H]DHS uptake in Escherichia coli K12 (ATCC 25868)1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID1629133Binding affinity to 16S rRNA A-site in Escherichia coli S30 extract assessed as inhibition of translation measured after 30 mins by coupled transcription/translation-based luciferase reporter gene assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID1629122Antimicrobial activity against Pseudomonas aeruginosa ATCC 47085 measured after 24 hrs by double-dilution method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID2940Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Which aminoglycoside ring is most important for binding? A hydropathic analysis of gentamicin, paromomycin, and analogues.
AID664698Antimicrobial activity against Staphylococcus aureus harboring ANT(4')-1 enzyme2011ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1629129Antimicrobial activity against Acinetobacter baumannii ATCC 19606 measured after 24 hrs by double-dilution method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID65065Percent killing of the total Escherichia coli K12 (ATCC 25868) cells at the C50 concentration was determined.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID278808Antibacterial activity against Pseudomonas aeruginosa ATCC 278532007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa.
AID65059Concentration required for half maximum rate of enhanced [3H]DHS uptake in Escherichia coli K121987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID1629124Antimicrobial activity against Haemophilus influenzae ATCC 49247 measured after 24 hrs by double-dilution method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID428869Antibacterial activity against Escherichia coli isolate ARS3 carrying pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID664697Antimicrobial activity against Staphylococcus aureus harboring APH(3'/5'''')-3 enzyme2011ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (110)

TimeframeStudies, This Drug (%)All Drugs %
pre-199050 (45.45)18.7374
1990's7 (6.36)18.2507
2000's27 (24.55)29.6817
2010's25 (22.73)24.3611
2020's1 (0.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.77 (24.57)
Research Supply Index4.78 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index30.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (2.61%)5.53%
Reviews3 (2.61%)6.00%
Case Studies4 (3.48%)4.05%
Observational0 (0.00%)0.25%
Other105 (91.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]